✦ LIBER ✦

PGS2: PHARMACOECONOMIC MODELING IN ASSISTED REPRODUCTION TECHNOLOGIES: RECOMBINANT FSH VERSUS URINARY FSH

✍ Scribed by JP Auray; G Duru; S Daya; W Ledger; K Silverberg; M Wikland; R Bouzayen; C Howies; A Beresniak

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Updated meta-analysis of recombinant fol

✍ Salim Daya 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Impact of urinary FSH price: a cost-effe

✍ K Silverberg; J Schertz; B Falk; A Beresniak 📂 Article 📅 2002 🏛 Reproductive Healthcare Ltd 🌐 English ⚖ 94 KB

PDB42 Economic Evaluation of Recombinant

✍ Fragoulakis, V.; Tarlatzis, B.; Mastrominas, M.; Maniadakis, N. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Does controlled ovarian stimulation (COS

✍ K. Mahmoud; F. Zhioua; M.H. Ben Aribia; F. Meherzi; J. Nemsia; M. Elouakdi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 35 KB

A Randomized Study of Recombinant Versus

✍ Q. Jie; Z. Guijin; H. Guoning 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Highly purified human menopausal gonadot

✍ Gautam Nand Allahbadia; Goral Neeraj Gandhi; Rubina Murtaza Merchant; Kaushal Sa 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 19 KB